Prostate cancer

Sandhu, Shahneen; Moore, Caroline M.; Chiong, Edmund; Beltran, Himisha; Bristow, Robert G.; Williams, Scott

doi:10.1016/s0140-6736(21)00950-8

Cited by 367 publications

(288 citation statements)

References 160 publications

Supporting

Mentioning

277

Contrasting

Unclassified

Order By: Relevance

“…In this study, at least 90% of prostate cancer cases were diagnosed at stage I and cancer-specific survival was at least 96% regardless of neighborhood SES, suggesting that patients were very likely to be cured from primary prostate cancer. 68 However, patients with lung cancer living in the most deprived neighborhood were more likely to be diagnosed at stage III and less likely to get surgery, which was considered to be the most curative treatment. 69 Thus, a large difference in cancer-specific survival between neighborhoods was observed among patients with lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Disadvantaged neighborhood-level and individual-level socioeconomic status (SES) have each been associated with suboptimal cancer care and inferior outcomes. However, independent or synergistic associations between neighborhood and individual socioeconomic disadvantage have not been fully examined, and prior studies using simplistic neighborhood SES measures may not comprehensively assess multiple aspects of neighborhood SES. OBJECTIVE To investigate the associations of neighborhood SES (using a validated comprehensive composite measure) and individual SES with survival among patients with nonmetastatic common cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For prostate cancer, the improvement of the therapeutic schedules is a compelling need, in particular for those cancer patients who progress to the lethal stage of mCRPC ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

et al. 2021

View full text Add to dashboard Cite

Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor tyrosine kinases (RTKs) involved in oncogenesis and angiogenesis. It is currently the standard therapy for medullary thyroid cancer (MTC), metastatic renal cell carcinoma (mRCC), and hepatocellular carcinoma (HCC). Combination of Cabozantinib with immunotherapy is now a standard treatment in metastatic renal cancer, and its efficacy is being tested in ongoing clinical trial in prostate cancer patients. Here, we report that Cabozantinib may exert an immunostimulatory role by inducing immunogenic stress of prostate cancer cells and directly modulating dendritic cells (DCs). Cabozantinib treatment arrested the cell cycle and triggered immunogenic cell death (ICD) in prostate cancer cells in vitro. Cabozantinib had a direct effect on DCs by the down-modulation of β-catenin and change in migratory and costimulatory phenotype of the DCs. These results may suggest possible immunomodulatory effects induced by Cabozantinib that could be exploited to optimize patient-tailored immunotherapeutic treatments.

show abstract

“…Although some patients with localized PCa can benefit from surgery or radiation therapy, relapse and metastasis occur in many patients [ 2 ]. Androgen deprivation therapy (ADT) is currently a standard treatment for prostate cancer; however, most patients eventually become resistant to this therapy during the course of treatment, leading to the expansion and spread of the cancer and resulting in a condition termed metastatic castration-resistant prostate cancer (mCRPC) [ 3 ]. Chemotherapeutic agents that have been approved for mCRPC treatment also cause severe resistance upon treatment initiation, leading to only moderately prolonged survival in the clinic [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer

Wang

Sun

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Immunotherapy has led to an expansion of the treatment of malignancies, but its effect in prostate cancer (PCa) patients is modest. Chemoimmunotherapy is a promising approach that has attracted substantial attention. Although the widely used clinical chemotherapeutic drug doxorubicin (DOX) elicits immunogenic cell death (ICD), its weak ICD effect and the abnormal vasculature of tumors severely limit its efficacy in chemoimmunotherapy. Ingenol-3-angelate (I3A), an emerging antitumor drug with dual chemotherapeutic and immune response-eliciting effects, is expected to exert synergistic effects when administered in combination with DOX. I3A induces the ICD of PCa cells by triggering mitophagy and apoptosis and promotes the normalization of tumor vessels, resulting in sufficient infiltration of immune cells into tumors. A synergistic effect of I3A and DOX was observed in vitro at a molar ratio of 1:4. To codeliver this ratio of I3A and DOX to tumor and ensure their uptake, we designed a dual-targeting delivery system, polylactide-poly(ethylene) glycol-2-(3-((S)-5-amino-1-carboxypentyl)-ureido) pentanedioate/triphenylphosphonium (PLA-PEG-ACUPA/TPP), which targets prostate-specific membrane antigen (PSMA) and mitochondria. Delivery of these nanomedicines led to inhibited tumor growth and a strong antitumor immune response. This study sheds light on the mitophagic and antiangiogenic mechanisms underlying I3A treatment of PCa and provides a strategy for combining vascular normalization and chemoimmunotherapy for PCa treatment.

show abstract

Prostate cancer

Cited by 367 publications

References 160 publications

Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers

Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer

Contact Info

Product

Resources

About